Optimizing Outcomes in Patients With NSCLC and Liver Metastases

Slides:

Advertisements

Similar presentations

Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.

Advertisements

Recent Advances in NSCLC Treatment

Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational.

Upfront Combination Therapy vs Step-Up Approach for PAH:

Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational.

advanced lung adenocarcinoma subtype

Challenges in RAS Wild-Type mCRC

New ESMO Guidance on Tumor Sidedness in mCRC

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Improving Survival in Glioblastoma Multiforme

Fundamental Concepts in the Diagnosis of Advanced NSCLC

New Patient Journeys in Non-small cell lung cancer

New Standards of Care in ALK-Translocated Advanced NSCLC

Neoadjuvant Therapy in HER2-Positive Breast Cancer

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Optimizing Outcomes in the Management of GIST

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

The Evolving Role of Immunotherapy in NSCLC

Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?

Basics of Immunotherapy Potential Therapeutic Targets.

Best Practices in Metastatic Colorectal Cancer

More Than Meets the Eye.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Moving Care Forward in Advanced NSCLC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Putting Evidence Into Practice: Highlights From Toronto

Progress of the NSCLC Revolution

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Current Challenges in Managing Hemophilia

The Changing Field of Melanoma: Ipilimumab.

Lunedì 04 giugno Highlight a cura di Filippo de Marinis

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Guidance on the Management of Pan-Negative NSCLC

Practical Strategies to Guideline-Recommended Biomarker Testing in NSCLC.

Debates and Dilemmas, Part 1

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Optimizing Characterization of NSCLC Through Specialty Collaboration

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

MX39795 Study Design Category 1 R 3:1 Category 2 Inclusion criteria

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

The Role of Measurable Residual Disease in AML

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Educational Objectives

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Moving Care Forward in Advanced Gastric Cancer

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Physiologic vs Chronologic Age

Minimal Residual Disease and Hematologic Malignancies

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Clinical Focus.

Combining Immunotherapy and Chemotherapy in NSCLC

Physiologic vs Chronologic Age

Opening remarks Welcome to CUP 2019: Cancer of Unknown Primary in the Era of Precision Medicine Focus: Contemporary Clinical Management and International.

Understanding the Expanding Armamentarium for GIST

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Updates in Best Practices in Non-Small Cell Lung Cancer

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Presentation transcript:

Optimizing Outcomes in Patients With NSCLC and Liver Metastases

Background on Liver Metastases

LM as a Negative Prognostic Factor

LM as a Negative Prognostic Factor (cont)

IMpower150: ICI + Anti-VEGFR + Chemo

Patient Management Strategies

IMpower150: EGFR or ALK Mutations

IMpower150: Liver Metastases

ECOG 4599: Carboplatin-Paclitaxel ± Bevacizumab

Challenges With Currently Approved ICIs

Does PD-L1 Level Correlate With Clinical Factors?

Future Possibilities for Bevacizumab-Containing Regimen

Clinical Challenges

Other Potential Metastatic Sites

Key Takeaways

Abbreviations